Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxandrolone
Drug ID BADD_D01634
Description A synthetic hormone with anabolic and androgenic properties.
Indications and Usage Use to promote weight gain after weight loss following extensive surgery.
Marketing Status approved; investigational
ATC Code A14AA08
DrugBank ID DB00621
KEGG ID D00462
MeSH ID D010074
PubChem ID 5878
TTD Drug ID D0U3GL
NDC Product Code 49884-301; 0245-0271; 0245-0272; 64181-0003; 63629-7603; 55486-1570; 62991-2699; 65129-1066; 51552-1579; 58159-046; 49884-302
UNII 7H6TM3CT4L
Synonyms Oxandrolone | Oxandrin | SC-11585 | SC 11585 | SC11585 | Anavar
Chemical Information
Molecular Formula C19H30O3
CAS Registry Number 53-39-4
SMILES CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.001---
Agitation17.02.05.012; 19.06.02.001--
Alanine aminotransferase13.03.04.002---
Aspartate aminotransferase13.03.04.008---
Azoospermia21.03.03.001--
Bladder irritation20.02.02.020---
Blood bilirubin increased13.03.04.018--
Blood calcium increased13.11.01.003---
Blood chloride increased13.11.01.005---
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood gonadotrophin decreased13.10.03.001---
Blood potassium increased13.11.01.011---
Bromosulphthalein test abnormal13.03.04.021---
Chronic obstructive pulmonary disease22.03.01.007---
Clitoral engorgement21.08.02.006---
Death08.04.01.001--
Depression19.15.01.001--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Electrolyte imbalance14.05.01.002---
Enlarged clitoris05.05.01.004; 21.08.02.001---
Epididymitis11.01.19.005; 21.09.02.001---
Epiphyses premature fusion05.05.03.002; 15.02.02.001---
Erection increased19.08.04.002; 21.03.01.004---
Fluid retention14.05.06.002; 20.01.02.003---
Glucose tolerance decreased13.02.02.004---
Gynaecomastia05.05.02.003; 21.05.04.003--
Haemoglobin13.01.05.018---
Hepatic necrosis09.01.07.002--
Hepatic neoplasm09.04.03.001; 16.07.03.001---
The 1th Page    1 2    Next   Last    Total 2 Pages